Impact of Missense Mutations on Spike Protein Stability and Binding Affinity in the Omicron Variant.

Publication date: Jul 17, 2024

The global effort to combat the COVID-19 pandemic faces ongoing uncertainty with the emergence of Variants of Concern featuring numerous mutations on the Spike (S) protein. In particular, the Omicron Variant is distinguished by 32 mutations, including 10 within its receptor-binding domain (RBD). These mutations significantly impact viral infectivity and the efficacy of vaccines and antibodies currently in use for therapeutic purposes. In our study, we employed structure-based computational saturation mutagenesis approaches to predict the effects of Omicron missense mutations on RBD stability and binding affinity, comparing them to the original Wuhan-Hu-1 strain. Our results predict that mutations such as G431W and P507W induce the most substantial destabilizations in the Wuhan-Hu-1-S/Omicron-S RBD. Notably, we postulate that mutations in the Omicron-S exhibit a higher percentage of enhancing binding affinity compared to Wuhan-S. We found that the mutations at residue positions G447, Y449, F456, F486, and S496 led to significant changes in binding affinity. In summary, our findings may shed light on the widespread prevalence of Omicron mutations in human populations. The Omicron mutations that potentially enhance their affinity for human receptors may facilitate increased viral binding and internalization in infected cells, thereby enhancing infectivity. This informs the development of new neutralizing antibodies capable of targeting Omicron’s immune-evading mutations, potentially aiding in the ongoing battle against the COVID-19 pandemic.

Open Access PDF

Concepts Keywords
Antibodies Antibodies, Neutralizing
Covid Antibodies, Neutralizing
F456 Antibodies, Viral
Mutations Antibodies, Viral
Viral Binding Sites
computational saturation mutagenesis
COVID-19
COVID-19
Humans
Mutation, Missense
Omicron Variant
Protein Binding
Protein Stability
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
Spike protein
spike protein, SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH uncertainty
disease IDO infectivity
drug DRUGBANK (S)-Des-Me-Ampa
disease VO USA
drug DRUGBANK Coenzyme M
disease VO Glycoprotein
disease IDO host
disease MESH infection
disease IDO process
disease VO Optaflu
disease MESH influenza
disease MESH aids
disease VO effective
disease VO URE
drug DRUGBANK L-Alanine
drug DRUGBANK Glycine
drug DRUGBANK Proline
drug DRUGBANK L-Tryptophan
drug DRUGBANK Alpha-Linolenic Acid
disease VO immunization
disease VO vaccine
disease MESH mutation rate
disease MESH HIV infection
pathway REACTOME HIV Infection
disease IDO virulence
drug DRUGBANK Amino acids
drug DRUGBANK Nitrogen
drug DRUGBANK Indole
disease IDO contagiousness
drug DRUGBANK Phenformin
disease MESH Social Vulnerability
disease VO ORF
drug DRUGBANK Angiotensin II
drug DRUGBANK Troleandomycin
disease IDO susceptibility
disease VO vaccinated
disease MESH Osteogenesis Imperfecta
drug DRUGBANK Guanosine
disease VO vaccine efficacy

Original Article

(Visited 1 times, 1 visits today)